A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease

García Campelo, María del Rosario

Estatísticas

Estatísticas

Ver Estatísticas de uso

Identificadores

Identificadores

URI: http://hdl.handle.net/20.500.11940/3872

ISSN: 0923-7534

Rexistro completo

Servizos

Servizos

RIS

Mendeley

Linksolver

Data de publicación

2015

Título da revista

ANNALS OF ONCOLOGY

Tipo de contido

Artigo